/RPTX
RPTX Stock - Repare Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$2.14-0.47%
$0.01 (-0.47%) • Dec 19
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.96
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.79
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+40.2%upside
Target: $3.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RPTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.12 – $2.16
TARGET (TP)$3.00
STOP LOSS$1.97
RISK/REWARD1:5.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.02
52W High$2.30
52W Low$0.89
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $53.48M | $51.13M | $131.83M | $7.60M | $135,000 |
| Gross Profit | $40.10M | $37.89M | $15.11M | $-80,254,000 | $-38,640,000 |
| Gross Margin | 75.0% | 74.1% | 11.5% | -1056.0% | -28622.2% |
| Operating Income | $-93,523,000 | $-116,224,000 | $-19,796,000 | $-108,660,000 | $-54,302,000 |
| Net Income | $-84,689,000 | $-93,796,000 | $-29,047,000 | $-106,908,000 | $-53,417,000 |
| Net Margin | -158.4% | -183.4% | -22.0% | -1406.7% | -39568.1% |
| EPS | $-2.00 | $-2.23 | $-0.69 | $-2.83 | $-1.45 |
Company Overview
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
33%
Hold / Neutral
2
67%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
1 Bullish2 Neutral/Bearish
Price Targets
$18
Average Target
↑ 717.8% Upside
Now
$11
Low
$18
Average
$28
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 9th 2023 | Stifel | Upgrade | Buy | $16← $11 |
| February 3rd 2023 | Morgan Stanley | Downgrade | Equal Weight | $15← $28 |
| January 6th 2023 | CapitalOne | Initiation | Overweight | $28 |
| April 12th 2022 | Stifel | Downgrade | Hold | $11 |
Earnings History & Surprises
RPTXBeat Rate
63%
Last 19 quarters
Avg Surprise
+121.3%
EPS vs Estimate
Beats / Misses
12/7
Last 12 quarters
Latest EPS
$0.08
Q4 2025
EPS Surprise History
Q1 24
-19.6%
$-0.67vs$-0.56
Q2 24
+1809.6%
$0.30vs$0.02
Q3 24
+3.5%
$-0.82vs$-0.85
Q4 24
+2.4%
$-0.81vs$-0.83
Q1 25
+13.0%
$-0.67vs$-0.77
Q2 25
-9.2%
$-0.71vs$-0.65
Q3 25
+30.4%
$-0.39vs$-0.56
Q4 25
+121.6%
$0.08vs$-0.35
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 2, 2026 | $-0.29 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.35 | $0.08 | +121.6% | ✓ BEAT |
Q3 2025 | Aug 8, 2025 | $-0.56 | $-0.39 | +30.4% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.65 | $-0.71 | -9.2% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $-0.77 | $-0.67 | +13.0% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.83 | $-0.81 | +2.4% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.85 | $-0.82 | +3.5% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $0.02 | $0.30 | +1809.6% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.56 | $-0.67 | -19.6% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.86 | $-0.45 | +47.7% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.83 | $-0.28 | +66.3% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.84 | $-0.83 | +1.2% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.73 | $-0.75 | -2.7% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.89 | $1.71 | +292.1% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.86 | $-0.91 | -5.8% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.89 | $-0.83 | +6.7% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.75 | $-0.70 | +6.7% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.70 | $-0.83 | -18.6% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.58 | $-0.71 | -22.4% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.49 | $-0.58 | -18.4% | ✗ MISS |
Latest News
Repare Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results. It also signed an agreement to be acquired by XenoTherapeutics for about $1.82 per share.
📈 PositiveBenzinga•Nov 17, 2025, 03:57 PM
Trading Halt: Halt status updated at 5:05:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Nov 14, 2025, 10:05 PM
Repare Therapeutics Q3 EPS $0.08 Beats $(0.12) Estimate, Sales $11.620M Beat $7.500M Estimate
📈 PositiveBenzinga•Nov 14, 2025, 09:47 PM
Repare Therapeutics Enters Agreement To Be Acquired By XenoTherapeutics, Xeno Acquisition For $1.82/Share In Cash
📈 PositiveBenzinga•Nov 14, 2025, 09:46 PM
Trading Halt: Halted at 4:36:08 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Nov 14, 2025, 09:36 PM
HC Wainwright & Co. Maintains Buy on Repare Therapeutics, Lowers Price Target to $3
➖ NeutralBenzinga•Oct 27, 2025, 01:34 PM
HC Wainwright & Co. Maintains Buy on Repare Therapeutics, Lowers Price Target to $3
➖ NeutralBenzinga•Oct 27, 2025, 01:34 PM
Repare Therapeutics To Share Initial Topline Safety, Tolerability And Early Efficacy Data From Phase 1 LIONS Trial In Poster Presentation At AACR-NCI-EORTC International Conference 2025
➖ NeutralBenzinga•Oct 13, 2025, 08:06 PM
Frequently Asked Questions about RPTX
What is RPTX's current stock price?
Repare Therapeutics Inc. (RPTX) is currently trading at $2.14 per share. The stock has moved -0.47% today.
What is the analyst price target for RPTX?
The average analyst price target for RPTX is $3.00, based on 1 analyst.
What sector is Repare Therapeutics Inc. in?
Repare Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RPTX's market cap?
Repare Therapeutics Inc. has a market capitalization of $0.09 billion, making it a small-cap company.
Does RPTX pay dividends?
No, Repare Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
ALXO
ALX Oncology Holdings Inc.
$1.45
Mkt Cap: $0.1B
ATYR
aTyr Pharma, Inc.
$0.75
Mkt Cap: $0.1B
BMEA
Biomea Fusion, Inc.
$1.40
Mkt Cap: $0.1B
CAMP
CAMP4 Therapeutics Corporation
$6.38
Mkt Cap: $0.1B
DTIL
Precision BioSciences, Inc.
$4.49
Mkt Cap: $0.1B
GUTS
Fractyl Health, Inc. Common Stock
$2.20
Mkt Cap: $0.2B
IMUX
Immunic, Inc.
$0.57
Mkt Cap: $0.1B
PMVP
PMV Pharmaceuticals, Inc.
$1.24
Mkt Cap: $0.1B
UNCY
Unicycive Therapeutics, Inc.
$5.56
Mkt Cap: $0.1B
Explore stocks similar to RPTX for comparison